Darren Willcox is named as a lobbyist on federal disclosure filings for 26 clients through W Strategies, LLC. The most recent filing naming them posted in October 2026. Issues reported include Medicare/Medicaid, Health Issues, Pharmacy and Medical/Disease Research/Clinical Labs.
Filers must list covered executive or legislative branch positions held. As filed:
| Client | Registrant | Latest | Issues |
|---|---|---|---|
| ABBVIE INC. | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid, Health Issues |
| DELFI DIAGNOSTICS | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid |
| INCYTE CORPORATION | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid, Health Issues |
| MEDTRONIC, INC. | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid |
| SANOFI U.S. SERVICES, INC. | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid |
| UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) | W STRATEGIES, LLC | Q3 2026 | Health Issues |
| PHLOW CORP. | W STRATEGIES, LLC | Q3 2026 | Pharmacy |
| PAPERBIRCH STRATEGIES ON BEHALF OF AP3 BIOMEDICAL | W STRATEGIES, LLC | Q3 2026 | Health Issues |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid, Pharmacy |
| MERCK & CO., INC. | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid, Health Issues |
| KAILERA THERAPEUTICS INC. | W STRATEGIES, LLC | Q3 2026 | Pharmacy |
| JUUL LABS INC | W STRATEGIES, LLC | Q3 2026 | Tobacco |
| IPSEN BIOPHARMACEUTICALS, INC. | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid |
| GLAXOSMITHKLINE | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid |
| GILEAD SCIENCES, INC. | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid, Health Issues |
| EXELIXIS, INC. | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid, Pharmacy |
| DYNE THERAPEUTICS, INC. | W STRATEGIES, LLC | Q3 2026 | Health Issues |
| CALIFORNIA LIFE SCIENCES | W STRATEGIES, LLC | Q3 2026 | Taxation/Internal Revenue Code, Medicare/Medicaid, Health Issues |
| BRISTOL-MYERS SQUIBB COMPANY | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid, Health Issues |
| ASTRAZENECA PHARMACEUTICALS LP | W STRATEGIES, LLC | Q3 2026 | Medicare/Medicaid, Health Issues |
| ALVEO TECHNOLOGIES | W STRATEGIES, LLC | Q3 2026 | Medical/Disease Research/Clinical Labs |
| ABBOTT LABORATORIES | W STRATEGIES, LLC | Q3 2026 | Health Issues |
| ELEVATEBIO | W STRATEGIES, LLC | Q4 2025 | Health Issues |
| SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS | W STRATEGIES, LLC | Q4 2025 | Health Issues |
| MCKESSON CORPORATION | W STRATEGIES, LLC | Q1 2025 | Pharmacy |
| Year | Clients | Registrants |
|---|---|---|
| 2026 | 23 | 1 |
| 2025 | 22 | 1 |
| Year | Items | Total |
|---|---|---|
| 2026 | 21 | $44K |
Pay is not disclosed for individual lobbyists. Filings do not confirm that records with the same name are one person, so this page may combine people who share the name Darren Willcox. See the Capitol Clarity rankings and method.